Company / Interest Expense
Summit Therapeutics Inc. Interest Expense History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$16.5M
FY2023
5-year range
$242.0K / $16.5M
FY2019-FY2023
Trend
+6702.1%
vs FY2022
Sector context
#22 of 44
Health Care
What the data says
Interest Expense changed +6702% YoY in FY2023, a notable deviation from the 5-year average annual change of +1326%.
Based on SEC 10-K filings.
$16M in FY2023 with a 5-year CAGR of +92.7%.
Increased from $242,000 to $16M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +301.1%
- 5-Year CAGR
- +92.7%
- 10-Year CAGR
- -
Sector benchmark
#23 of 44 in Health CareTop 50% of 44This company $16.5M Sector average $291.0M
▼
-94.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +92.7%, indicating consistent growth.
- In FY2023, interest expense increased 6702.1% year-over-year.
- Ranks #22 out of 44 companies in the Health Care sector.
- Lowest interest expense in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $16.5M | +6702.1% |
| FY2022 | $242.0K | +0.0% |
| FY2021 | $242.0K | -5.1% |
| FY2020 | $255.0K | -12.4% |
| FY2019 | $291.0K | -53.1% |
| FY2018 | $620.0K | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026